secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2026-06-03T21:22:06+00:00
Accession:  0001493152-26-027132
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus
--------------------------------------------------------------------------------

- Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.
- Gonzalez has 20+ years biotech experience; previously CCO at Alume Biosciences, CEO at Navidea.
- Company sharpens focus on longevity, regenerative medicine; cenplacel-L sees physician demand in Florida.
- Out-licensed biomaterials to NexGel for up to $30M, reducing liabilities by ~$13M (previously announced).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/0001493152-26-027132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315226027132/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer